Antiviral Antisense Oligomer Targeting SARS-CoV-2 Genome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of established therapies for SARS-CoV-2, SARS-CoV-1, and MERS-CoV, which are part of the same genus Betacoronavirus and cause viral infectious diseases.
Innovation Solution
Development of an antisense oligomer targeting specific regions of the genome RNA of SARS-CoV-2, which is complementary to sequences in regions such as the 5′ UTR, nsp1, nsp10, RNA-dependent RNA polymerase, ORF10, and 3′ UTR, to inhibit viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral agents are used against SARS-CoV-2, then treatment is attempted, but clinical effectiveness is unproven and no established therapy exists
Solution Approach 1:
The patent changes the fundamental parameter of antiviral approach by using antisense oligomers with specific base sequences (15-30 bases) complementary to target regions in the viral genome RNA. This molecular-level parameter change enables direct interference with viral replication mechanisms, achieving both reliability in effectiveness and ease in establishing a new therapy framework.
Solution Approach 2:
The patent extracts and targets specific functional regions of the viral genome (5' UTR, nsp1, nsp10, RNA-dependent RNA polymerase, ORF10, 3' UTR) to disrupt essential viral processes. By isolating and attacking these critical regions, the therapy achieves reliable antiviral effects while providing a clear pathway for establishing treatment protocols.
2Adaptability or versatility
If no established therapy exists for SARS-CoV-2, SARS-CoV-1, and MERS-CoV, then new therapeutic agents are desired, but development time and validation are required
Solution Approach 1:
The patent achieves universality by designing antisense oligomers that can target multiple coronavirus strains (SARS-CoV-2, SARS-CoV-1, MERS-CoV) through conservation of specific genomic regions. The same therapeutic approach and molecular mechanism apply across all three viruses, enabling broad spectral coverage without requiring separate development timelines for each pathogen.
Solution Approach 2:
The patent performs preliminary action by identifying and targeting conserved regions in the viral genomes before full-scale therapeutic deployment. The selection of target regions (5' UTR, nsp1, nsp10, RNA-dependent RNA polymerase, ORF10, 3' UTR) is based on pre-characterized viral genetics, allowing rapid progression from concept to clinical application across different coronavirus strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligomer demonstrates antiviral effects on SARS-CoV-2, SARS-CoV-1, and MERS-CoV, potentially providing a therapeutic and prophylactic option with high inhibitory effects on viral growth and minimal side effects.
Implementation Method 1
comprising a base sequence complementary to a base sequence in a target region
Data Source
AI summary
The present specification provides an antisense oligomer, or a pharmaceutically acceptable salt thereof, or a hydrate of the antisense oligomer or the salt having a length of 15 to 30 bases, comprising a base sequence complementary to a base sequence in a target region, wherein the target region comprises a sequence of at least 10 consecutive bases in at least one region selected from the group consisting of a 5′ UTR region, a nsp1 region, a nsp10 region, an RNA-dependent RNA polymerase region, an ORF10 region, and a 3′ UTR region in the genome RNA of SARS-CoV-2, or a complementary sequence thereof, wherein the antisense oligomer, or the pharmaceutically acceptable salt thereof, or the hydrate of the antisense oligomer or the salt has an antiviral effect on a virus selected from the group consisting of SARS-CoV-2, SARS-CoV-1, and MERS-CoV.